Skip to main content

Day: August 27, 2020

Dimensional Fund Advisors Ltd. : Form 8.3 – SDL plc – Ordinary shares

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 44,424 shares.All interests and all short positions should be disclosed.Details of any open stock-settled derivative...

Continue reading

Leiðrétting: Almenna leigufélagið ehf.: Árshlutareikningur fyrri árshelmings 2020

Rangt ártal birtist í fyrirsögn fyrstu fréttatilkynningar vegna birtingar árshlutareiknings fyrri árshelmings 2020. Allar aðrar upplýsingar og gögn standa óbreytt, en eru einnig hér í viðhengi. Á fundi sínum í dag samþykkti stjórn Almenna leigufélagsins ehf. árshlutareikning samstæðunnar fyrir fyrri árshelming 2020Rekstrartekjur samstæðunnar voru 1.335 m.kr. á tímabilinu. Þá var EBITDA (rekstrarhagnaður fyrir matsbreytingu, afskriftir og fjármagnsliði) 748 m.kr. fyrir tímabilið. Tap varð af rekstri samstæðunnar á tímabilinu að fjárhæð 281 m.kr., þar af er neikvæð matsbreyting að fjárhæð 424 m.kr. sem má að mestu leyti rekja til breytinga í skammtímahorfum í rekstri hótelíbúða samstæðunnar. Handbært fé frá rekstri nam 317 m.kr. og jókst um 182 m.kr. frá fyrra ári.  Heildareignir samstæðunnar námu 46.611 m.kr. 30. júní 2020, en þar af voru...

Continue reading

AVX Releases New Miniature, High-CV Tantalum Chip Capacitors Optimized for Automotive Applications

FOUNTAIN INN, S.C., Aug. 27, 2020 (GLOBE NEWSWIRE) — AVX Corporation, a leading manufacturer and supplier of advanced electronic components and interconnect, sensor, control, and antenna solutions, released a new series of high-CV resin-molded, surface-mount tantalum chip capacitors with a miniature and low-profile facedown design optimized for automotive electronics applications. The new F98-AJ6 Series capacitors are currently available in miniature 0603 and 0805 chip sizes with maximum heights of just 1.0mm and 0.80±0.10mm, respectively, and feature facedown under-tab terminations designed to achieve high capacitance, high volumetric efficiency, and high PCB assembly densities and help conserve board space and reduce costs. The series also features the industry’s smallest and highest-CV 0603 tantalum capacitor rated at 10μF/10V...

Continue reading

Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Company to Acquire Worldwide Rights for Development of IMT504 Boca Raton, FL, Aug. 27, 2020 (GLOBE NEWSWIRE) — Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a term sheet with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire all necessary rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies worldwide. IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines. Importantly, IMT504 has been granted orphan drug designation in the US, which provides significant benefits including tax credits, market exclusivity and waiver of...

Continue reading

PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS

HANOVER, MD, Aug. 27, 2020 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a contingent precedent exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to interfere with the anticancer activity.Fluoropyrimidines are still the cornerstone of treatment for many different types of cancers, either as monotherapy or in combination with other chemotherapy agents. Capecitabine, an oral prodrug of 5-FU, is approved as first-line therapy for metastatic colorectal and breast...

Continue reading

Hammer Fiber Optics Holdings Corp Rolls Out HammerCall – Conferencing and Collaboration

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) — Hammer Fiber Optics Holdings Corp (OTCQB: HMMR) subsidiary 1stPoint Communications rolled out its new HammerCall application suite. The first phase includes video and audio conferencing, text, chat and webinar functionality. In subsequent phases the application will evolve into a full business telephony system capable of replacing even the most modern Voice-Over-IP phone systems entirely with mobile devices.The basic version is free to use, clients will have an easy signup process using a web portal. Advanced versions will be priced competitively compared to competitors in the market, offering higher capacity than most, greater storage and recording times, as well as text messaging capabilities. HammerCall is currently supported on all major platforms through traditional web browsers. Applications...

Continue reading

SIMLAT Selects Draganfly’s Vital Intelligence Technology to Combat the Spread of COVID-19

Draganfly’s platform to be used in improving the scope of unmanned systems by first responders in handling pandemic situationsLos Angeles, CA, Aug. 27, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (“UAV”), Remotely Piloted Aircraft Systems (“RPAS”), and Unmanned Vehicle Systems (“UVS”) sectors, is pleased to announce that Simlat has selected to incorporate Draganfly’s Vital Intelligence Technology within their Specto platform to assist first responders in handling pandemic situations.Simlat, based in Israel and the United States, is a leading provider of next generation simulation solutions for Unmanned Aerial Systems (UAS). Simlat has developed the Specto (also called the...

Continue reading

Siguldas CMAS JSC Unaudited interim report for the first six months of 2020

Company’s net turnover in the first six months of 2020 was 598.6 thousand euros, which is by 5.7% higher than in the first six months of 2019, whereas Company’s profit before enterprise income tax was 68.3 thousand euros – by 20.5% or 11.6 thousand euros higher compared to the corresponding period in 2019.PROFIT OR LOSS ACCOUNTJSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ is one of the largest high-quality breeding bull semen producers and suppliers in Latvia. The second largest field of the Company’s basic economic activities is milk testing services. The Company also provides other breeding related services – consultations on issues of cattle breeding, feeding and keeping, evaluation of cow exterior, artificial insemination of cows, initial processing of the monitoring data.Valda MālnieceMember of the Management...

Continue reading

Siguldas CMAS, AS, nerevidēts starpperiodu pārskats par pirmajiem sešiem 2020. gada mēnešiem

2020. gada pirmajos sešos mēnešos neto apgrozījums bija 598,6 tūkst. eiro, kas ir par 5,7% vairāk nekā iepriekšējā gada pirmajos sešos mēnešos, bet peļņa pirms uzņēmumu ienākuma nodokļa bija 68,3 tūkst. eiro – par 20,5% jeb 11,6 tūkst. eiro lielāka, salīdzinot ar iepriekšējā gada attiecīgo periodu.PEĻŅAS VAI ZAUDĒJUMU APRĒĶINSAS „Siguldas ciltslietu un mākslīgās apsēklošanas stacija” ir viens no lielākajiem augstvērtīgas vaislas buļļu spermas ražotājiem un piegādātājiem Latvijā. Otra lielākā Sabiedrības pamatdarbības nozare ir piena analīžu veikšana. Sabiedrība veic arī citus ar ciltsdarbu saistītus pakalpojumus – konsultācijas liellopu selekcijas, ēdināšanas un turēšanas jautājumos, govju eksterjera vērtēšanu, govju mākslīgo apsēklošanu, pārraudzības datu pirmapstrādi.Valda MālnieceValdes locekle, Finanšu un grāmatvedības daļas vadītājaTālrunis:...

Continue reading

HIGHCO : Mise a disposition du Rapport Financier semestriel 2020

Aix-en-Provence, le 27 août 2020 (15h)MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2020HighCo annonce ce jour avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier semestriel au 30 juin 2020.Ce rapport financier semestriel peut être consulté sur le site internet de la Société à l’adresse www.highco.com, dans la rubrique « Investisseurs – Information réglementée – Rapport Financier Semestriel ».Il est tenu à la disposition du public dans les conditions prévues par la réglementation en vigueur et intègre le rapport d’activité du premier semestre 2020, les états financiers consolidés condensés semestriels, la déclaration de la personne physique responsable du rapport financier semestriel ainsi que le rapport des Commissaires aux comptes sur l’information financière semestrielle.A...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.